Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Jun 27, 2018 9:00am EDT

CohBar Added to Russell 2000® Index

Jun 25, 2018 12:08pm EDT

CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions

Jun 07, 2018 8:59am EDT

CohBar Announces the Appointment of Dr. Philippe Calais to its Board

Jun 06, 2018 9:45am EDT

CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018

May 29, 2018 9:00am EDT

CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions

May 15, 2018 4:03pm EDT

CohBar, Inc. Announces First Quarter 2018 Financial Results

Apr 18, 2018 4:05pm EDT

CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange

Apr 13, 2018 4:05pm EDT

CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000

Apr 02, 2018 4:03pm EDT

CohBar, Inc. Announces Fourth Quarter 2017 Financial Results

Mar 29, 2018 4:10pm EDT

CohBar, Inc. Announces Closing of First Tranche of Private Placement